Pharma
Supriya Lifescience Ltd
SUPRIYA · NSE · INE07RO01027Wednesday, 9 Sept 2026Vol: 9.6L traded · 26.3% delivered2:17 pm
Market Cap₹7,366 Cr
P/E37.2
P/B6.2
EPS₹24.61
Div Yield0.1%
ROE19.1%
ROCE22.2%
ROE19.1%
1Y Return+13.32%
Avg. Volume0.4M
Delivery %26.28%
Price Chart
52-Week Range
About
Supriya Lifescience Ltd is a Pharma company listed on NSE.
Technicals
Free account
Register freeTechnicals
Create a free account to view momentum, moving averages, and delivery signals.
Quant
Premium
UpgradeQuant metrics
Upgrade to view volatility, drawdown, factor, and risk metrics.
Key Ratios
Market Cap₹7,366 Cr
Current Price₹915.25
52W High / Low₹1,085 / ₹545.5
Stock P/E37.2
Price to Book6.2
EPS (TTM)₹24.61
Dividend Yield0.1%
ROE19.1%
1Y Return+13.32%
Day Change-0.04%
Profit & Loss
| Period | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Sales | ₹802 Cr | ₹680 Cr | ₹557 Cr | |
| Expenses | ₹548 Cr | ₹444 Cr | ₹400 Cr | |
| Operating Profit | ₹255 Cr | ₹236 Cr | ₹158 Cr | |
| OPM % | 31.7% | 34.7% | 28.3% | |
| Other Income | ₹0 Cr | ₹10 Cr | ₹0 Cr | |
| Depreciation | ₹28 Cr | ₹20 Cr | ₹16 Cr | |
| Interest | ₹1 Cr | ₹0 Cr | ₹4 Cr | |
| Profit Before Tax | ₹275 Cr | ₹248 Cr | ₹166 Cr | |
| Tax | ₹66 Cr | ₹61 Cr | ₹47 Cr | |
| Net Profit | ₹209 Cr | ₹188 Cr | ₹119 Cr | |
| EPS (₹) | 26.0 | 23.4 | 14.8 | |
| Dividend Payout % | — | — | — |
Financial history locked
Register freeRegister free to see 1 more year.
Quarterly Results
| Quarter | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Sales | ₹190 Cr | ₹277 Cr | ₹206 Cr | ₹200 Cr | |
| Expenses | ₹151 Cr | ₹187 Cr | ₹141 Cr | ₹134 Cr | |
| Operating Profit | ₹39 Cr | ₹89 Cr | ₹65 Cr | ₹66 Cr | |
| OPM % | 20.3% | 32.2% | 31.6% | 33.0% | |
| Depreciation | — | — | — | — | |
| Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | |
| Net Profit | ₹24 Cr | ₹74 Cr | ₹50 Cr | ₹50 Cr | |
| EPS (₹) | 3.0 | 9.2 | 6.2 | 6.3 |
Quarterly history locked
Register freeRegister free to see 1 more quarter.
Balance Sheet
| Period | FY26 | FY25 | FY24 | FY23 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹16 Cr | ₹16 Cr | ₹16 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹1,182 Cr | ₹981 Cr | ₹799 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹5 Cr | ₹5 Cr | ₹5 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹154 Cr | ₹115 Cr | ₹101 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹1,357 Cr | ₹1,117 Cr | ₹921 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹723 Cr | ₹609 Cr | ₹457 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹41 Cr | ₹3 Cr | ₹7 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | ₹219 Cr | ₹134 Cr | ₹112 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | ₹160 Cr | ₹118 Cr | ₹85 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | ₹37 Cr | ₹76 Cr | ₹68 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹176 Cr | ₹176 Cr | ₹192 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹1,357 Cr | ₹1,117 Cr | ₹921 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance sheet history locked
Register freeRegister free to see 1 more year.
Cash Flow
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| FY26 | ₹186 Cr | ₹-176 Cr | ₹-10 Cr | ₹-0 Cr |
| FY25 | ₹165 Cr | ₹-152 Cr | ₹-8 Cr | ₹4 Cr |
| FY24 | ₹113 Cr | ₹-174 Cr | ₹-22 Cr | ₹-83 Cr |
| FY23 |
Cash flow history locked
Register freeRegister free to see 1 more year.
Peer Comparison
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | — | — | +14.78% | +7.18% |
| Dr Reddys Laboratories Ltd | — | — | +8.84% | -3.74% |
| Cipla Ltd | — | — | +11.77% | -5.50% |
| Apollo Hospitals Enterprise Ltd | — | — | +22.64% | +23.01% |
| Divis Laboratories Ltd | ₹2,50,065 Cr | 83.9 | +16.5% | +46.29% |
Mutual Fund Holdings
Free account
Register freeMutual fund holdings
Create a free account to see institutional ownership snapshots.
Bulk & Block Deals
Free account
Register freeBulk & block deals
Create a free account to view recent institutional deal activity.
Analyst Estimates
Free account
Register freeAnalyst estimates
Create a free account to view analyst estimate summaries.
Latest News
2026-09-02Intimation Under Regulation 30 Regarding Letter Dispatched To The Shareholders Of The CompanyBSE Filing2026-08-17Supriya Lifescience Ltd (BOM:543434) (Q1 2027) Earnings Call Highlights: Revenue Surges 31% to ...GuruFocus.com2026-06-05Supriya Lifescience Ltd (BOM:543434) Q4 2026 Earnings Call Highlights: Record Revenue Growth ...GuruFocus.com
Documents & Filings
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.